Prime MedicinePRME
NASDAQBiotech
No cached AI snapshot yet for PRME.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
146 employees180.55M shares outstandinglisted 2022-10-20dividend yield 86.71%
Next earnings ~May 5, 2026 · Ex-dividend Sep 10, 2019 · Dividend $0.80 quarterly
About Prime Medicine
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Latest News
Showing market-wide stock news
Euro: 1.150 target nears on Fed risk against US Dollar – ING
WTI falls near $100 as Saudi adds Oman route, US stocks surge
Yield on 10-year Treasury hovers above 5% as investors await Fed decision
Warsh’s Fed expected to hike rates 25bp as dot plot takes center stage
USD/JPY Price Forecast: Retreats from 155.50 with Fed’s policy in focus
Equities: Fed focus and energy shock – Deutsche Bank
Related Stocksin Biotech
Ready to see the live AI view on PRME?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing PRME side-by-side with live signals.